Small Symbol. Big Update: Changes to the Authorized Representative Symbol

In 2025, this standard was amended through EN ISO 15223-1:2021/A1:2025, introducing a new defined term, ‘authorized representative’, and updating the long-established 'EC REP' symbol. While the change may appear minor, it represents an important step toward greater international harmonization of medical device labelling and allows using the authorized representative concept in other global jurisdictions.

What is the standard about?

EN ISO 15223-1 provides a set of standardized symbols that manufacturers can use in place of text on medical device labels, packaging, and accompanying information. The standard helps communicate essential information such as the manufacturer, batch code, serial number, date of manufacture, storage conditions, and authorized representative details. By using symbols instead of lengthy text translations, manufacturers can conserve valuable label space while improving consistency and usability across international markets.

The standard is particularly important because medical device information must be understood by healthcare professionals, distributors, regulators, and patients worldwide. Consistent symbols help reduce the risk of misinterpretation while supporting global trade, regulatory compliance, and safe use of medical devices.

What does the amendment change?

The amendment introduces two significant updates.

First, it adds a formal definition of authorized representative to the standard. This acknowledges the growing use of authorized representatives in jurisdictions around the world, not only within Europe.

Second, and more visibly, it changes the authorized representative symbol itself. Historically, the symbol contained the text 'EC REP', referring to an authorized representative in the European Community or European Union. The amendment replaces the fixed 'EC' designation with the variable format 'XX REP', where ‘XX’ can be replaced by a country code or other text specified by the relevant regulatory authority.

Through Commission Implementing Decision (CID) 2026/1231 and supporting MDCG guidance, the European Commission specifies for the European Union that 'EU REP' should now be used to identify an authorized representative established within the Union. Under the amended standard, the generic 'XX REP' symbol is therefore rendered as 'EU REP' for devices placed on the EU market.

The amendment also includes examples showing how the same symbol framework could be adapted for other jurisdictions, such as 'UK REP', 'CH REP' or other country-specific authorized representative designations, if required by local regulations.

Why is it important?

At first glance, changing two letters on a symbol may seem insignificant. However, the amendment addresses several important challenges.

Most significantly for the EU Commission, it modernizes the terminology. The EC abbreviation refers to the European Community, a term that no longer reflects the current political and regulatory structure of the European Union. The move to 'EU REP' aligns the symbol with contemporary regulatory language and with requests from the European Commission.

The amendment also supports international harmonization. By creating a generic authorized representative symbol that can be adapted for different jurisdictions, EN ISO 15223-1 provides a globally applicable solution instead of one tied exclusively to Europe. This helps regulators and manufacturers avoid creating multiple unrelated symbols for essentially the same concept.

Importantly, regulatory authorities have clarified that the transition from 'EC REP' to 'EU REP' is primarily an editorial terminology update. It does not alter the legal role, responsibilities, location requirements or obligations of authorized representatives, nor does it affect the safety, performance or intended purpose of medical devices.

What are the benefits of the updated standard?

For industry, the amendment provides greater flexibility and future-proofs the standard. Manufacturers operating in multiple jurisdictions can use a common symbol framework rather than developing unique graphical symbols for each market. This reduces complexity, supports consistent global labelling strategies, and simplifies regulatory compliance activities.

However, implementing the change is far more complex than simply replacing one letter with another. Medical device labels appear on products, packaging, instructions for use, regulatory submissions, artwork files, enterprise systems, and manufacturing processes. Recognizing this complexity, the European Commission established a five-year (60-month) transition and coexistence period following the harmonization of EN ISO 15223-1:2021/A1:2025. During this period, both the 'EC REP' and 'EU REP' symbols may continue to be used, allowing manufacturers to incorporate the change through routine product updates and packaging revisions rather than undertaking costly, large-scale relabelling programmes.

For society, the benefits are less visible but equally important. While the Authorized Representative symbol does not directly affect device users, patients or device safety, it forms part of a broader system of standardized medical device communication. Healthcare professionals and patients benefit from clear, consistent, internationally recognized symbols that reduce language barriers and improve understanding of important product information. Standardized symbols help promote consistency across markets, support regulatory transparency, and contribute to the safe and effective use of medical devices worldwide.

What are the practical applications?

The amended symbol is used on medical device labels, packaging, instructions for use, electronic labelling, and other manufacturer-supplied information where an authorized representative must be identified. The symbol appears adjacent to the authorized representative’s name and address and serves as a concise visual indicator of the representative’s contact information.

Manufacturers introducing new products into the European market can now implement the 'EU REP' symbol as part of their labelling strategy. Likewise, organizations selling products globally can leverage the flexibility of the revised symbol structure to support emerging authorized representative requirements in additional jurisdictions.

Looking Ahead

The amendment to EN ISO 15223-1 demonstrates how even a seemingly small change to a symbol can have wide-reaching implications. By modernizing terminology, enabling global application, and improving regulatory alignment, the new authorized representative symbol strengthens the role of international standards in supporting safe, effective, and accessible medical device communication worldwide.